SymBio Pharmaceuticals EBIT per Share
The EBIT per Share of SymBio Pharmaceuticals (4582.T) as of Nov 15, 2026 is -88.44 JPY. In the previous year, EBIT per Share was -84.58 JPY — a change of 4.57% (lower).
Get this data via API
Financial Data API
EBIT per Share
-88.44JPY
YoY
4.57%
Last updated:
The SymBio Pharmaceuticals EBIT per Share history
3 Years
10 Years
25 Years
Max
| YEAR | EBIT per Share | YoY |
|---|---|---|
| est | 0.00JPY | -100.00% |
| -88.44JPY | +4.57% | |
| -84.58JPY | +323.36% | |
| -19.98JPY | -139.28% | |
| 50.86JPY | +103.28% | |
| 25.02JPY | -121.20% | |
| -118.02JPY | -25.05% | |
| -157.45JPY | +19.37% | |
| -131.90JPY | -52.38% | |
| -277.01JPY | +44.22% | |
| -192.07JPY | -39.05% | |
| -315.11JPY | +95.79% | |
| -160.94JPY | -26.65% | |
| -219.43JPY | -30.98% | |
| -317.92JPY | -46.05% | |
| -589.23JPY | +149.09% | |
| -236.55JPY | +77.03% | |
| -133.62JPY | -7,778.30% | |
| 1.74JPY | -100.63% | |
| -277.40JPY | +88.06% | |
| -147.50JPY | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
SymBio Pharmaceuticals Stock analysis
Frequently Asked Questions about SymBio Pharmaceuticals stock
EBIT per Share of SymBio Pharmaceuticals is -88.44 JPY in 2025.
EBIT per Share of SymBio Pharmaceuticals changed from -84.58 JPY to -88.44 JPY, representing a 4.57% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Share SymBio Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Income Statement — SymBio Pharmaceuticals
All Key Metrics — SymBio Pharmaceuticals
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth